These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ; Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312 [TBL] [Abstract][Full Text] [Related]
10. Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Erdim R; Erciyes D; Görmez S; Karabay KO; Catakoğlu AB; Aytekin V; Demiroğlu C; Gülbaran M Anadolu Kardiyol Derg; 2010 Aug; 10(4):340-5. PubMed ID: 20693130 [TBL] [Abstract][Full Text] [Related]
11. Current strategies with high-dose tirofiban. Mukherjee D; Roffi M Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
15. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Junghans U; Seitz RJ; Aulich A; Freund HJ; Siebler M Cerebrovasc Dis; 2001; 12(4):308-12. PubMed ID: 11721100 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609 [TBL] [Abstract][Full Text] [Related]
17. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial. Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742 [TBL] [Abstract][Full Text] [Related]
18. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results. Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054 [TBL] [Abstract][Full Text] [Related]